February 2024 - Page 3 of 13

CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10

By Ran Zhang 2024.02.26

Introduction:Diabetes and liver diseases are common chronic conditions in China, and they interact in terms of pathogenesis, clinical manifestations, and therapeutic targets, often posing mutual risk factors. Co-management of these…

Impact of Treatment Adjustments on the Prognosis of “T+A” Therapy in Unresectable Hepatocellular Carcinoma

By Ran Zhang 2024.02.26

Editor's Note: The combination of atezolizumab and bevacizumab ("T+A") has emerged as the first-line standard treatment for unresectable hepatocellular carcinoma (uHCC) and is widely used in clinical practice. However, the…

Expert Insights | Dr. LechengYu: Is Mass Screening Necessary for HBV Infection in the General Population?

By Ran Zhang 2024.02.26

Editor's Note: Currently, the treatment rate for chronic hepatitis B (CHB) patients in China still needs improvement. China has a vast territory and a large population, raising the question of whether…

Striking Hard to Overcome the Final “Fortress” of Antiviral Treatment for Hepatitis C

By Ran Zhang 2024.02.26

Editor's Note: The advent of direct-acting antiviral drugs (DAAs) for chronic hepatitis C has achieved virological clearance in antiviral treatment, a crucial step towards China's realization of the World Health Organization's…

Dr.JianWu: How to Prevent and Treat Overlooked “Hepatitis E”?

By Ran Zhang 2024.02.26

Editor's note: Among the five common viral hepatitis types (A, B, C, D, and E), although Hepatitis E virus (HEV) is the latest discovered hepatotropic virus in humans, its incidence of…

Understanding and Managing Chronic Hepatitis B: The Importance of Detailed Assessment

By Ran Zhang 2024.02.26

By Shuquan Cheng Chief Physician, Department of Hepatology, Third People's Hospital of Guilin Since the introduction of the first oral nucleos(t)ide analogs (NAs) lamivudine for the treatment of chronic hepatitis…

Dr. Jidong Jia: Advances in Diagnosis and Treatment of Non-Cirrhotic Portal Hypertension

By Ran Zhang 2024.02.26

Editor's note: Portal hypertension is defined as a pathologically elevated pressure in the portal venous system. While the most common cause is cirrhosis, it can also occur without cirrhosis, known…

Interview with Recipient of the “Huaxia Youth Medical Science and Technology Award”

By Ran Zhang 2024.02.26

This interview features Dr. Xiaolong Qi, a recipient of the Huaxia Youth Medical Science and Technology Award, one of the most prestigious awards in the Chinese medical field. The Huaxia…

“The Natural Course of Portal Vein Thrombosis in Cirrhosis.”

By Ran Zhang 2024.02.26

The "Hepatology Digest -Liver Vascular Diseases Column" , initiated by Dr. Xingshun Qi of the Northern Theater Command General Hospital's Department of Gastroenterology at the invitation of the "Hepatology Digest"…

Chinese scientist awarded for groundbreaking work in transplantation, cellular therapy

By Lisa Cui 2024.02.25

Huang Xiaojun speaks with a patient at Peking University People's Hospital in Beijing, capital of China, July 6, 2023. (Xinhua/Zhang Yuwei) SAN ANTONIO, the United States, Feb. 24 (Xinhua) --…